MTOR and breast cancer: Based on emerging preclinical and clinical studies, combinational treatment of targeted drugs (e.g. mTOR inhibitor everolimus 2, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palbociclib 3) with endocrine therapy has prolonged progression-free survival (PFS) in certain BC patients.